• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Octapharma’s Acquired Coagulation Factor Deficiency Medication Receives FDA Approval


Balfaxar indicated for restoration of blood coagulation.

Platelets forming a blood clot, AI Generative. Image Credit: Adobe Stock Images/Катерина Євтехова

Image Credit: Adobe Stock Images/Катерина Євтехова

Octapharma, a human protein product manufacturer, has announced the FDA approval of Balfaxar, a treatment for acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures. According to the company, the medication works to replenish deficient clotting factors due to warfarin therapy, ultimately restoring blood coagulation.

“The FDA approval of Balfaxar® establishes a new therapy for medical providers when their patients need a 4F-PCC product,” said Flemming Nielsen, President, Octapharma USA, in a company press release. "Octapharma is committed to providing patients with lifesaving and life-enhancing therapies for critical care medicine. We are confident Balfaxar® will be a welcomed treatment for physicians who need to quickly restore patients’ coagulation.”

Reference: Octapharma's Prothrombin Complex Concentrate, Balfaxar®, Receives FDA Approval For Warfarin Reversal in Urgent Surgery & Invasive Procedures. Octapharma USA. July 26, 2023. Accessed July 27, 2023. https://www.octapharmausa.com/news/press-release/2023/octapharmas-prothrombin-complex-concentrate-balfaxar-receives-fda-approval-for-warfarin-reversal-in-urgent-surgery-invasive-procedures

Related Videos
Related Content